多发性硬化症患者报告的药物治疗诊所药物利用计划的结果;对自我注射疾病修饰疗法的受控前后研究
Ghader Mohammadnezhad1, Yasaman Khajeamiri2, Shirin Khosravani2
1Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
BMC research notes
|July 18, 2025
概括
药剂师教育干预显著改善了对多发性硬化症 (MS) 患者的干扰素βs的知识. 这种干预措施提高了对疾病修饰疗法的理解,并优化了患者的护理.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 临床药房实践 临床药房实践
- 神经科学和神经病学 神经科学和神经病学
背景情况:
- 药剂师在管理多发性硬化症 (MS) 患者,解决药物和设备利用方面发挥着至关重要的作用.
- 干扰素βs是MS的关键疾病修饰疗法,需要适当的患者理解和坚持.
- 关于干扰素βs的低最佳知识可能会导致不适当的使用,并降低MS患者的治疗效果.
研究的目的:
- 评估药剂师教育干预 (PEI) 对伊朗多发性硬化症患者使用干扰素β的临床影响.
- 通过药剂师参与专门的药物治疗诊所,优化药物利用计划.
- 评估PEI对患者知识,副作用管理和MS症状控制的影响.
主要方法:
- 采用受控前后调查设计,使用15项验证问卷.
- 问卷评估了患者对正确的干扰素-β 管理,减轻不良影响和症状管理的知识.
- 100名患有多发性硬化症且接受了至少一年的干扰素β治疗的患者在PEI前后填写了问卷.
主要成果:
- 患者知识分数显著改善,从干预前的4.90 ± 5.79提高到干预后的14.44 ± 0.99 (P < 0.001).
- 发现患者对干扰素βs的知识存在显著差距,即使在长期治疗后也是如此.
- 该PEI证明了对提高患者对MS治疗的理解有显著的积极影响.
结论:
- 药剂师教育干预有效地提高了MS患者对疾病修饰疗法的药物治疗知识和意识.
- 药剂师领导的管理护理对于优化治疗结果和减少与多发性硬化症相关的临床负担至关重要.
- PEI代表了一种有价值的策略,可以改善MS患者的自我管理和对干扰素β治疗的坚持.
相关概念视频
Drug Therapy
103
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
103
Drug Delivery: Miscellaneous Routes
468
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
468
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drug Dosage Regimen: Overview
3.8K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
Inflammatory Bowel Disease IV: Pharmacological Management
196
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
196


